HighTower Advisors’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
HighTower Advisors's VKTX Position: Q3 2026 in Review
HighTower Advisors increased its Viking Therapeutics (VKTX) stake by 15% in Q3 2026, buying an estimated $32.6K and bringing the position to 7,037 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #3439.
HighTower Advisors first reported a position in VKTX in Q3 2018 and has held it in 18 quarters since. The position peaked at $507K in Q3 2024. 357 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.
- HighTower Advisors held 7,037 shares of Viking Therapeutics worth $229K as of Q3 2026.
- HighTower Advisors bought 941 Viking Therapeutics shares in Q3 2026, an estimated $32.6K.
- Viking Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3439 holding.
- HighTower Advisors first reported a position in Viking Therapeutics in Q3 2018 and has held it in 18 quarters since.
- HighTower Advisors's Viking Therapeutics position peaked at $507K in Q3 2024.
- 357 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.